Compile Data Set for Download or QSAR
Report error Found 61 Enz. Inhib. hit(s) with all data for entry = 10745
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563268(US11407740, Compound 171)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563298(US11407740, Compound 299)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563294(US11407740, Compound 289)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563275(US11407740, Compound 193)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563273(US11407740, Compound 191)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563269(US11407740, Compound 172)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563124(US11407740, Compound 7)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563267(US11407740, Compound 169)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563263(US11407740, Compound 141)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563262(US11407740, Compound 139)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563259(US11407740, Compound 130)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563255(US11407740, Compound 65)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563154(US11407740, Compound 38)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563144(US11407740, Compound 17)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563146(US11407740, Compound 19 | US11407740, Compound 20)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563285(US11407740, Compound 209)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563272(US11407740, Compound 177)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563152(US11407740, Compound 23)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563274(US11407740, Compound 192)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563276(US11407740, Compound 194)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563277(US11407740, Compound 199)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563279(US11407740, Compound 201)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563280(US11407740, Compound 202)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563125(US11407740, Compound 14)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563286(US11407740, Compound 210)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563287(US11407740, Compound 211)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563292(US11407740, Compound 287)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563293(US11407740, Compound 288)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563295(US11407740, Compound 296)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563296(US11407740, Compound 297)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563270(US11407740, Compound 173)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563254(US11407740, Compound 64)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563180(US11407740, Compound 60)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563256(US11407740, Compound 68 | 6-(3-(((S)-1-fluoropropa...)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563257(US11407740, Compound 71)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563258(US11407740, Compound 101)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563175(US11407740, Compound 57)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563261(US11407740, Compound 138)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563174(US11407740, Compound 56)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563271(US11407740, Compound 174)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563155(US11407740, Compound 43)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563156(US11407740, Compound 44)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563160(US11407740, Compound 54)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563265(US11407740, Compound 148)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563224(US11407740, Compound 61)
Affinity DataIC50: 75nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563284(US11407740, Compound 208)
Affinity DataIC50: 75nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563146(US11407740, Compound 19 | US11407740, Compound 20)
Affinity DataIC50: 550nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 61 total ) | Next | Last >>
Jump to: